Jingfang Pharmaceuticals-B (02595) molecular gel Pan RAS (ON) inhibitor GFH276 has enrolled the first patient for the Phase I/II clinical trial for the treatment of cancer patients with RAS mutations.

Zhtng Cijng APP news, Jin Fang Pharmaceuticals-B (02595) announced that the first patient in the phase I/II trial of GFH276 for the treatment of RAS mutant advanced solid tumors has recently completed enrollment. The National Medical Products Administration approved GFH276 to enter an open-label and multicenter clinical trial application in early September. This product is a molecular glue Pan RAS (ON) inhibitor developed independently by Jin Fang, with global rights.